|Continually increasing market and regulatory pressures are causing life science organizations to reassess their safety and risk management strategies. For smaller companies, waiting to consolidate safety databases or build a pharmacovigilance strategy can have significant consequences and impact filings. In addition, mid to large companies are constantly reassessing their safety structure, technology and models.
It is becoming progressively more important for organizations to be proactive and invest in agile, compliant pharmacovigilance solutions.Many factors impact the optimum solution, including company size, clinical trial phase, ability to scale, therapeutic area, globalization plans and much more. When properly implemented, an integrated services and technology approach can help:
– Build efficiency by driving down operational costs
Download our whitepaper to learn how Sciformix uses a comprehensive, full life cycle methodology for pharmacovigilance activities, from consulting, database consolation, medical contact center and case processing operations to the complex functions of aggregate reporting, signal detection, real world evidence & market access.